Medical Benefits
Medical Benefits
Standard on the new 4008A, DIASAFE® plus enables the safe production of ultrapure dialysis fluid that can contribute to:
I Lead the Change
Tell Me More

References

  1. Baz M, Durand C, Ragon A, Jaber K, Andrieu D, Merzouk T, Purgus R, Olmer M, Reynier JP, Berland Y: Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14: 681–685.
  2. Furuya R et al. Ultrapure Dialysate Reduces Plasma Levels of ß2-Microglobulin and Pentosidine in Hemodialysis Patients. Blood Purif 2005;23: 311–316.
  3. Gejyo F, Yamada T, Odani S. A new form of amyloid protein associated with chronic hemodialysis was identified as B2 -microglobulin. Biochem Biophys Res Commun 1985; 129:701–706.
  4. Lederer SR, Schiffl H. Ultrapure Dialysis Fluid Lowers the Cardiovascular Morbidity in Patients on Maintenance Hemodialysis by Reducing Continuous Microinflammation. Nephron 2002; 91: 452–455.
  5. Liyanage T et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. 
    www.thelancet.com Published online March 13, 2015 http://dx.doi.org/10.1016/S0140-6736(14)61601-9
  6. Miyata T, Inagi R, Iida Y. Involvement of B2 – macroglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93: 521–528.
  7. Miyata T, Oda O, Inagi R. B2 -Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243–1252. 
  8. Obi Y., Rhee C., Mathew A. Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. J Am Soc Nephrol 2016; 27: 3758–3768 
  9. Schiffl H. Nephrol Dial Transplant. 2000; 15(6):840-5. Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux 
  10. Schiffl H et al. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17: 1814–1818. 
  11. Shafi T., Jaar B., Plantinga L. Association of Residual Urine Output With Mortality, Quality of Life, and Inflammation in Incident Hemodialysis Patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 2010; 56:348-358 
  12. Sitter Tet al. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 2107–1211. 
  13. Termorshuizen F., Dekker F.Van Manen J. Relative Contribution of Residual Renal Function and Different Measures of Adequacy to Survival in Hemodialysis Patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15: 1061–1070